Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
$10.43+0.04%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+268.6%
The outlook
Artiva Biotherapeutics, Inc. currently reads as bullish based on above its 50- & 200-day averages, 67% of the way from its 52-week low to high, avg target +243% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range67% of the way from its 52-week low to high
Price targetAvg target +243% vs current price
Analyst price target
~12-month · 5 analysts$35.80average target+243.2% vs now
Now $10.43
Low $23.00High $41.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$506.8M
52-wk high
$14.53
52-wk low
$2.22
50-day avg
$8.91
200-day avg
$6.44
Trailing P/E
—